Format

Send to

Choose Destination
J Arthroplasty. 2015 Feb;30(2):192-5. doi: 10.1016/j.arth.2014.08.020. Epub 2014 Sep 6.

Does tranexamic acid reduce blood transfusion cost for primary total hip arthroplasty? A case-control study.

Author information

1
Virginia Tech Carilion School of Medicine, Roanoke, Virginia.
2
Orthopaedic Surgery, Carilion Clinic, Virginia Tech Carilion School of Medicine, Roanoke, Virginia; Surgery, Virginia Tech Carilion School of Medicine, Roanoke, Virginia.
3
Bensol, Warsaw, Indiana.

Abstract

Peri-operative tranexamic acid (TXA) significantly reduces the need for allogeneic blood transfusion in total hip arthroplasty (THA) and thus hospital costs are reduced. Before employing TXA in primary THA at our institution, facility costs were $286.90/THA for blood transfusion and required 0.45 man-hours/THA (transfusion rate 19.87%). After incorporating TXA, the cost for intravenous application was $123.38/THA for blood transfusion and TXA medication and 0.07 man-hours/THA (transfusion rate 4.39%) and the cost for topical application was $132.41/THA for blood transfusion and TXA and 0.14 man-hours/THA (transfusion rate 12.86%). TXA has the potential to reduce the facility cost per THA and the man-hours/THA from blood transfusions.

KEYWORDS:

cost; hip arthroplasty; tranexamic acid; transfusion

PMID:
25534861
DOI:
10.1016/j.arth.2014.08.020
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center